Compare · BFRG vs NVO
BFRG vs NVO
Side-by-side comparison of Bullfrog AI Holdings Inc. (BFRG) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BFRG and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 14730.1x BFRG ($12.4M).
- Over the past year, BFRG is down 59.9% and NVO is down 45.7% - NVO leads by 14.2 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for BFRG).
- NVO has more recent analyst coverage (25 ratings vs 0 for BFRG).
- Company
- Bullfrog AI Holdings Inc.
- Novo Nordisk A/S
- Price
- $0.69+4.36%
- $41.01-4.51%
- Market cap
- $12.4M
- $183.15B
- 1M return
- +4.99%
- -10.44%
- 1Y return
- -59.89%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BFRG
- BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform
- SEC Form S-1 filed by Bullfrog AI Holdings Inc.
- SEC Form 10-Q filed by Bullfrog AI Holdings Inc.
- SEC Form DEFA14A filed by Bullfrog AI Holdings Inc.
- SEC Form DEF 14A filed by Bullfrog AI Holdings Inc.
- Bullfrog AI Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BullFrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement
- Bullfrog AI Holdings Inc. filed SEC Form 8-K: Shareholder Director Nominations, Financial Statements and Exhibits
- BullFrog AI Announces Participation at AACR Annual Meeting
- Bullfrog AI Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care